| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1984) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | C04AD03 |
| UNII: | SD6QCT3TSU |
Structure
| InChI Key | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C13H18N4O3 |
| Molecular Weight | 278.31 |
| AlogP | 0.19 |
| Hydrogen Bond Acceptor | 7.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 78.89 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 20.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | 3',5'-cyclic phosphodiesterase inhibitor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Hydrolase
|
- | 6600 | - | - | ||
|
Enzyme
Phosphodiesterase
Phosphodiesterase 4
Phosphodiesterase 4A
|
- | 168000 | - | 37700 | - | |
|
Enzyme
Phosphodiesterase
Phosphodiesterase 4
Phosphodiesterase 4B
|
- | - | - | 37700 | - | |
|
Enzyme
Phosphodiesterase
Phosphodiesterase 4
Phosphodiesterase 4C
|
- | - | - | 37700 | - | |
|
Enzyme
Phosphodiesterase
Phosphodiesterase 4
Phosphodiesterase 4D
|
- | - | - | 37700 | - | |
|
Enzyme
Transferase
|
- | - | - | - | 0.3738 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | 2.73-9.08 | |
|
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Nucleotide-like receptor (family A GPCR)
Adenosine receptor
|
- | - | - | 180000 | - | |
|
Secreted protein
|
- | 85000 | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 77.22 |
Metabolites
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hepatitis, Alcoholic | 3 | D006519 | ClinicalTrials |
| Brachial Plexus Neuropathies | 3 | D020516 | ClinicalTrials |
| Endometriosis | 3 | D004715 | ClinicalTrials |
| Enterocolitis, Necrotizing | 3 | D020345 | ClinicalTrials |
| Jaundice | 3 | D007565 | ClinicalTrials |
| Osteonecrosis | 3 | D010020 | ClinicalTrials |
| Nephrotic Syndrome | 3 | D009404 | ClinicalTrials |
| Renal Insufficiency, Chronic | 3 | D051436 | ClinicalTrials |
| Neonatal Sepsis | 3 | D000071074 | ClinicalTrials |
| Liver Cirrhosis | 3 | D008103 | ClinicalTrials |
| Liver Failure | 3 | D017093 | ClinicalTrials |
| Glomerulonephritis | 3 | D005921 | ClinicalTrials |
| Kidney Failure, Chronic | 3 | D007676 | ClinicalTrials |
| Osteonecrosis | 3 | D010020 | ClinicalTrials |
| Non-alcoholic Fatty Liver Disease | 2 | D065626 | ClinicalTrials |
| Liver Cirrhosis, Biliary | 2 | D008105 | ClinicalTrials |
| Ductus Arteriosus, Patent | 2 | D004374 | ClinicalTrials |
| Behcet Syndrome | 2 | D001528 | ClinicalTrials |
| Acute Coronary Syndrome | 2 | D054058 | ClinicalTrials |
| Depressive Disorder, Major | 2 | D003865 | ClinicalTrials |
| Post-Acute COVID-19 Syndrome | 2 | D000094024 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 2 | D002289 | ClinicalTrials |
| Leishmaniasis, Cutaneous | 2 | D016773 | ClinicalTrials |
| Acute Kidney Injury | 2 | D058186 | ClinicalTrials |
| Fatty Liver | 2 | D005234 | ClinicalTrials |
| Sarcoidosis, Pulmonary | 2 | D017565 | ClinicalTrials |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | D054198 | ClinicalTrials |
| Diabetic Nephropathies | 2 | D003928 | ClinicalTrials |
| Wounds and Injuries | 2 | D014947 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Head and Neck Neoplasms | 2 | D006258 | ClinicalTrials |
| Leishmaniasis | 2 | D007896 | ClinicalTrials |
| Brain Diseases | 2 | D001927 | ClinicalTrials |
| Fibrosis | 2 | D005355 | ClinicalTrials |
| Malaria, Falciparum | 2 | D016778 | ClinicalTrials |
| Coronary Disease | 2 | D003327 | ClinicalTrials |
| Depressive Disorder | 2 | D003866 | ClinicalTrials |
| Biliary Atresia | 2 | D001656 | ClinicalTrials |
| Epilepsy | 2 | D004827 | ClinicalTrials |
| Inflammatory Bowel Diseases | 2 | D015212 | ClinicalTrials |
| Neoplasms | 2 | D009369 | ClinicalTrials |
| Sexually Transmitted Diseases | 2 | D012749 | ClinicalTrials |
| Liver Diseases | 2 | D008107 | ClinicalTrials |
| Heart Diseases | 2 | D006331 | ClinicalTrials |
| Parkinson Disease | 2 | D010300 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Bipolar Disorder | 1 | D001714 | ClinicalTrials |
| Pancreatitis | 1 | D010195 | ClinicalTrials |
| HIV Infections | 1 | D015658 | ClinicalTrials |
| Hermanski-Pudlak Syndrome | 1 | D022861 | ClinicalTrials |
| Pancreatitis | 1 | D010195 | ClinicalTrials |
| Crohn Disease | 1 | D003424 | ClinicalTrials |
| Central Nervous System Neoplasms | 1 | D016543 | ClinicalTrials |
| Severe Acute Respiratory Syndrome | 1 | D045169 | ClinicalTrials |
| Alopecia Areata | 1 | D000506 | ClinicalTrials |
| Schizophrenia | 1 | D012559 | ClinicalTrials |
| Oral Submucous Fibrosis | 1 | D009914 | ClinicalTrials |
| Muscular Dystrophy, Duchenne | 1 | D020388 | ClinicalTrials |
| Infertility | 1 | D007246 | ClinicalTrials |
| Cognitive Dysfunction | 1 | D060825 | ClinicalTrials |
| Anemia | 1 | D000740 | ClinicalTrials |
Related Entries
MCS
Scaffolds
Side Effects from Label
Side Effects (PT)
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 6493-05-6 |
| ChEBI | 7986 |
| ChEMBL | CHEMBL628 |
| DrugBank | DB00806 |
| DrugCentral | 2099 |
| EPA CompTox | DTXSID7023437 |
| FDA SRS | SD6QCT3TSU |
| Human Metabolome Database | HMDB14944 |
| Guide to Pharmacology | 7095 |
| KEGG | C07424 |
| PDB | PNX |
| PharmGKB | PA450864 |
| PubChem | 4740 |
| SureChEMBL | SCHEMBL34039 |
| ZINC | ZINC000001530776 |
CONTENTS